Synthesis and biological evaluation of diaryl urea derivatives designed as potential anticarcinoma agents using de novo structure-based lead optimization approach
作者:Fereshteh Azimian、Maryam Hamzeh-Mivehroud、Javid Shahbazi Mojarrad、Salar Hemmati、Siavoush Dastmalchi
DOI:10.1016/j.ejmech.2020.112461
日期:2020.9
compounds based on sorafenib were designed, synthesized and biologically evaluated. Using de novo design method, a library of new ligands was generated and expanded. Considering in silico binding affinity towards VEGFR2, synthetic feasibility, and drug-likeness property, some of the designed ligands were selected for synthesis and screening for their in vitro antiproliferative activities against two cancer
为了开发阻断VEGFR2和Raf / MEK / ERK丝裂原活化的蛋白激酶信号通路的抑制剂,设计,合成和生物学评估了基于索拉非尼的新化合物。使用从头设计方法,生成并扩展了新的配体库。考虑到对VEGFR2的计算机结合亲和力,合成可行性和药物相似性,选择了一些设计的配体进行合成,并筛选了它们对两种癌细胞系(HT-29和A549)的体外抗增殖活性。四种化合物(13a,14a,14l和15b)显示出更强的抗增殖活性(IC 50为与阳性参考药物索拉非尼(IC 50 = 17.28μM)相比,针对HT-29细胞的HT-29值分别为13.27、6.62、12.74、3.38μM)。值得注意的是,化合物15b表现出最高的活性,尤其是它诱导HT-29凋亡,增加细胞内活性氧水平,将细胞周期阻滞在G0 / G1期,并影响凋亡相关蛋白和细胞周期相关蛋白的表达。15b化合物可有效阻断Raf / MEK / ER